Heart-Type Fatty Acid-Binding Protein Is More Sensitive Than Troponin T to Detect the Ongoing Myocardial Damage in Chronic Heart Failure Patients

Niizeki, Takeshi; Takeishi, Yasuchika; Arimoto, Takanori; Takabatake, Noriaki; Nakatani, Naoki; Hirono, Osamu; Watanabe, Tetsu; Nitobe, Joji; Harada, Mutsuo; Suzuki, Satoshi; Koyama, Yo; Kitahara, Tatsuro; Sasaki, Toshiki; Kubota, Isao

doi:10.1016/j.cardfail.2006.10.014

Cited by 91 publications

(90 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…H-FABP levels were measured using a 2-step sandwich enzymelinked immunosorbent assay (ELISA) kit (MARKIT-M H-FABP, Dainippon Pharmaceutical Co Ltd, Tokyo, Japan) as previously reported. 6 PTX3 Plasma PTX3 levels were measured using the ELISA kit (Perseus Proteomics Inc, Tokyo, Japan) as previously reported. 7 The analytical range of these kits was 4.0-2,000 pg/ml for BNP assay, 1.1-250 ng/ml for H-FABP assay, and 0.1-20 ng/ml for PTX3 assay.…”

Section: Assays Of Bnp H-fabp and Ptx3mentioning

confidence: 99%

Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3

Ishino

Takeishi

Niizeki

et al. 2008

Circ J

Self Cite

View full text Add to dashboard Cite

Section: Assays Of Bnp H-fabp and Ptx3mentioning

confidence: 99%

Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3

Ishino

Takeishi

Niizeki

et al. 2008

Circ J

Self Cite

View full text Add to dashboard Cite

“…It was shown to be a sensitive and early marker of myocardial damage in ACS in many studies (4)(5)(6)(7)(8). In addition, it was indicated that high plasma H-FABP levels in the different processes of myocardial damage, such as heart failure, have been associated with poor prognosis and cardiovascular events in the future (9)(10)(11)(12). Although many studies have been conducted on H-FABP levels in ACS and other cardiac pathologic courses accompanying myocardial damage, studies evaluating whether these levels are affected by temporary myocardial ischemia in patients with stable CAD are very rare.…”

Section: Introductionmentioning

confidence: 99%

Relationship between heart-type fatty acid-binding protein levels and coronary artery disease in exercise stress testing: an observational study

Arı¹,

Tokaç²,

Alihanoğlu³

et al. 2011

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Objective: Although, there has been great improvement on the diagnosis and early treatment of acute coronary syndromes, especially in terms of myocardial damage biochemical markers, we do not have a specific marker yet, for using the diagnosis of stable coronary artery disease (CAD). This study aimed to evaluate the relationship between CAD and the changes of heart-type fatty acid binding protein (H-FABP) levels before and after exercise stress testing (EST). Methods: A total of 47 patients were enrolled in this observational study. Of 47 patients, 21 had normal coronary anatomy; the remaining 26 patients had coronary lesions over 70% in at least one major coronary artery. All patients performed EST. Along with this, H-FABP levels before EST and at peak exercise, 1 st hour, 3 rd hour (3h), were measured in all patients. Differences among the measurements were evaluated through the Friedman test and Wilcoxon test, and the Bonferroni correction was applied to determine which measurement caused the difference. Results: Contrary to expectations, the means of the H-FABP values measured at particular intervals for each group tended to decline from the basal level to the 3h level. When the difference between the 3h measurement and the basal level was compared in each group, the decreasing was statistically significant in both groups (p<0.05). A statistically significant decrease at the 3h measurement compared to the basal level in the CAD group was more apparent than in the control group (2.790±2.569ng/ml vs. 0.837±2.070ng/ml, p=0.009). Conclusion: We found that H-FABP levels did not increase during EST and contrary to expectation, were inclined to decrease. We thought that decreasing H-FABP levels likely resulted from exercise-induced proteinuria. (Anadolu Kardiyol Derg 2011; 11: 685-91) Key words: Coronary artery disease, heart-type fatty acid binding protein, exercise stress testing 685 ÖZET Amaç: Akut koroner sendrom tanısı ve erken tedavisinde özellikle miyokardiyal hasar belirteçlerinde sağlanan ilerleme ile önemli bir mesafe alınmasına rağmen stabil koroner arter hastalığı (KAH) tanısında kullanılabilecek özel bir markır henüz yoktur. Bu çalışmada egzersiz stres testi (EST) öncesi ve sonrası H-FABP düzeylerindeki değişim ile koroner arter hastalığı arasındaki ilişki araştırılmıştır. Yöntemler: Gözlemsel çalışmamıza en az bir majör koroner arterinde %70 ve üzerinde darlığı olan 26 hasta ve koroner arterleri normal bulunan 21 hasta olmak üzere toplam 47 hasta alındı. Tüm hastalara EST yapıldı. Tüm hastalarda bazal, pik egzersiz, 1. saat ve 3. saatte H-FABP ölçümü yapıldı. Ölçümler arası farka Friedman Testi ile bakıldı, farkın hangi ölçümden kaynaklandığını bulmak için Bonferroni düzeltmeli Wilcoxon Testi kullanıldı. Bulgular: Her bir grupta belirlenen zaman aralığında ölçülen H-FABP değerleri ortalamaları beklenenin aksine bazaldan üçüncü saate azalma eğiliminde idi. Üçüncü saat ile bazal ölçümler arasındaki farklar (fark 3) grup içinde karşılaştırıldığında her iki grupta da azalma anlamlı idi (p<0.05). H...

show abstract

“…35) Niizeki, et al measured serum H-FABP and troponin T levels in 126 consecutive heart failure patients at hospital admission. 36) They found that the positive rate of H-FABP was higher than that of troponin T in all heart failure patients (46% [58/126] versus 26% [33/126], P < 0.0001), and in severe heart failure (NYHA III/IV) patients (69% [34/49] versus 47% [23/49], P = 0.0121). The area under the receiver operating characteristic (ROC) curve was higher for H-FABP than for troponin T (0.779 versus 0.581, P = 0.009), suggesting that H-FABP had greater predictive capacity to identify high-risk patients than troponin T. However, it should be noted that serum H-FABP levels were affected by age, gender, obesity, and renal function in a large group of volunteers (n = 2,099).…”

Section: )mentioning

confidence: 99%

Biomarkers in Heart Failure

Takeishi

2014

Int. Heart J.

Self Cite

View full text Add to dashboard Cite

SummaryAppropriate use of biomarkers is clinically important for identifying heart failure in its early stage, optimizing risk stratification, and managing patients. This article describes established and traditional biomarkers as well as novel biomarkers reflective of myocardial stress, myocardial damage, extracellular matrix, oxidative stress, inflammation, renal function, micro RNAs, and heart failure with preserved left ventricular ejection fraction. This review focuses on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice. (Int Heart J 2014; 55: 474-481) Key words: BNP, NT-proBNP, ST2, Troponin, H-FABP, Galectin-3, Cystatin C, Pentraxin 3 C ardiovascular diseases are the predominant cause of death in developed countries. Among the afflicted, patients with heart failure are increasing, and this complex syndrome is becoming a public health problem, especially with the aging of populations. To establish diagnostic, therapeutic, and prognostic strategies, the identification of reliable biomarkers for heart failure is necessary.1,2) Although a number of biomarkers have been developed, the ideal biomarkers should meet certain criteria: 1) non-invasive sample collection, 2) a high degree of sensitivity and specificity, 3) able to detect the disease at an early stage, 4) sensitivity high enough to reflect relevant changes in disease conditions, 5) a long halflife within the sample, 6) rapid measurement system responding to clinical needs, and 7) low cost. 3,4) In this article, the focus will be on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice. Myocardial Stress MarkersB-type natriuretic peptide: B-type natriuretic peptide (BNP) is a well-established biomarker, extensively used for the diagnosis and prognosis of patients with heart failure. BNP is a cardiac hormone, identified as the second compound of the natriuretic peptide family and secreted predominantly from the ventricle in response to mechanical overload. 5) In the failing heart, increased wall stress and neurohormonal activation facilitate BNP secretion chiefly from ventricular myocytes. BNP promotes diuresis, vasodilatation, and attenuation of renin and aldosterone secretion. Tsutamoto, et al initially measured plasma levels of BNP in 85 patients with chronic heart failure and a left ventricular ejection fraction (LVEF) of less than 0.45. 6)The plasma levels of BNP increased in proportion to the severity of heart failure. Plasma levels of BNP were 5-fold higher in non-survivors than in survivors. Among clinical and hemodynamic parameters, Cox proportional hazard analysis revealed that only plasma BNP (P < 0.0001) and pulmonary capillary wedge pressure (P = 0.003) were significant independent predictors of mortality in patients with heart failure. Plasma levels of BNP provided prognostic information independent of other variables previously associated with a poor prognosis. To date, a number of studies have r...

show abstract

Heart-Type Fatty Acid-Binding Protein Is More Sensitive Than Troponin T to Detect the Ongoing Myocardial Damage in Chronic Heart Failure Patients

Cited by 91 publications

References 21 publications

Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3

Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3

Relationship between heart-type fatty acid-binding protein levels and coronary artery disease in exercise stress testing: an observational study

Biomarkers in Heart Failure

Contact Info

Product

Resources

About